WILLIAM G WIERDA to Models, Biological
This is a "connection" page, showing publications WILLIAM G WIERDA has written about Models, Biological.
Connection Strength
0.514
-
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. Am J Hematol. 2021 02 01; 96(2):241-250.
Score: 0.099
-
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 2018 03 15; 124(6):1160-1168.
Score: 0.081
-
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 2014 Jun 26; 123(26):4132-5.
Score: 0.063
-
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10.
Score: 0.063
-
Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. J Clin Pharmacol. 2014 Jul; 54(7):818-27.
Score: 0.062
-
Prediction model for mortality after intracranial hemorrhage in patients with leukemia. Am J Hematol. 2011 Jul; 86(7):546-9.
Score: 0.051
-
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma. 2007 Oct; 48(10):1931-9.
Score: 0.040
-
Genetics and molecular biology of chronic lymphocytic leukemia. Curr Treat Options Oncol. 2005 May; 6(3):215-25.
Score: 0.034
-
A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia. PLoS One. 2011; 6(12):e28277.
Score: 0.013
-
Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. Biol Blood Marrow Transplant. 2003 Jun; 9(6):364-72.
Score: 0.007